FDA finalizes psychedelic-assisted therapy guidance and schedules public hearing for September 2026

Overview

The U.S. Food and Drug Administration has finalized its industry guidance document for psychedelic-assisted therapy development programs, establishing a formal regulatory framework for clinical trials involving psilocybin, MDMA, and other psychedelic compounds. The guidance, released in mid-2026, addresses longstanding uncertainty about how psychedelic therapies — which combine a controlled substance with a structured psychotherapy protocol — should be evaluated within the existing drug approval framework.

A public hearing has been scheduled for September 2026 to gather stakeholder input on implementation details, including therapist qualifications, treatment setting standards, and post-marketing surveillance requirements.

Key Regulatory Clarifications

1. Trial design requirements — phase 2/3 trials must use randomized, controlled designs with active placebo comparators (not just passive placebo), and must separately evaluate the drug effect from the therapy effect
2. Therapist training standards — the guidance defines minimum training requirements for therapists administering psychedelic-assisted sessions, including clinical hours, certification, and ongoing supervision
3. Safety monitoring — enhanced monitoring protocols for psychiatric adverse events, including mandatory 24-hour post-dosing observation, standardized suicidality assessment at all timepoints, and 12-month follow-up for delayed adverse events
4. Risk Evaluation and Mitigation Strategy (REMS) — all approved psychedelic therapies will require a REMS program limiting administration to certified treatment centers

Why This Matters for Body-Mind Practice

The FDA guidance effectively creates the regulatory architecture for a new category of nervous system therapeutics — one that explicitly integrates pharmacology with structured psychological and somatic practices. For body-mind practitioners, the guidance requirement for trained therapeutic support during psychedelic sessions creates a formal clinical role for professionals skilled in breathwork, somatic awareness, and integration practices. The September hearing offers an opportunity for the body-mind community to provide input on therapist training standards and treatment protocols.

Source

• FDA guidance on psychedelic-assisted therapy. — U.S. Food and Drug Administration